Brief: Eledon Pharmaceuticals Says First Patient Dosed In Phase 1B Trial Evaluating Tegoprubart In Kidney Transplantation
18/07/2022 13:56
July 18 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O :
* ELEDON PHARMACEUTICALS ANNOUNCES THE FIRST PATIENT DOSED
IN
PHASE 1B TRIAL EVALUATING TEGOPRUBART IN KIDNEY TRANSPLANTATION
Source text for Eikon: ID:nGNX38bmQd
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial